Merit Medical to Participate at the J.P. Morgan Healthcare Conference
Rhea-AI Summary
Merit Medical (NASDAQ: MMSI) will participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, January 12-15, 2026. Management will present a company overview on Tuesday, January 13, 2026 at 4:30 PM PT / 7:30 PM ET.
Martha G. Aronson, President and CEO, and Raul Parra, CFO, will deliver the presentation. A live audio webcast will be accessible via Merit’s investor relations "Events" page, and presentation materials will be posted to Merit’s investor relations "Investor Events and Presentations" page. A replay will be available on the site for approximately 90 days.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, MMSI declined 0.33%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers showed mixed moves: several names like TFX, RGEN, and ICUI were up between 0.93 and 2.12 while BLCO was slightly down -0.24. Only BLCO had similar J.P. Morgan conference news, suggesting today’s headline is mainly company-specific rather than a broad sector driver.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 13 | Reimbursement update | Neutral | -0.8% | CMS deferral but start of full U.S. commercialization and reiterated WRAPSODY forecast. |
| Nov 05 | Clinical trial data | Positive | -1.5% | WAVE trial AVF arm showed superior 24‑month patency vs. PTA in hemodialysis patients. |
| Nov 03 | Clinical trial data | Positive | -0.2% | Non‑randomized AVG cohort met patency performance goals with strong 6–24 month outcomes. |
| Oct 30 | Earnings & guidance | Positive | +2.0% | Q3 2025 revenue growth, margin improvement, and raised 2025 revenue and EPS guidance. |
| Oct 15 | Acquisition | Positive | +0.4% | Agreement to acquire C2 CryoBalloon technology with expected future revenue contribution. |
Recent positive clinical, commercial, and acquisition updates have sometimes been met with modest share price weakness, while strong earnings and guidance have coincided with positive reactions.
Over the last few months, Merit Medical reported key developments, including WRAPSODY reimbursement strategy changes on Nov 13, 2025 and multiple 24‑month WAVE trial readouts in early November. Q3 2025 results on Oct 30, 2025 showed revenue of $384.2M and raised full‑year guidance, which drew a positive price reaction. The C2 CryoBalloon acquisition agreement on Oct 15, 2025 also saw a modestly positive move. Against this backdrop, the J.P. Morgan conference participation news fits as an investor-relations and visibility event rather than a new financial or clinical catalyst.
Market Pulse Summary
This announcement highlights Merit Medical’s participation in a major healthcare investor conference, where management plans to present an overview and update. With recent milestones spanning WRAPSODY clinical data, reimbursement strategy, Q3 2025 results, and acquisition activity, investors may watch this event for refreshed commentary on growth priorities and integration progress. Key items to monitor include any updates to prior guidance, commercialization timelines, or strategic focus areas outlined in earlier releases.
AI-generated analysis. Not financial advice.
SOUTH JORDAN, Utah, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader in healthcare technology, today announced that management will participate in the 44th Annual J.P. Morgan Healthcare Conference, which is being held at The Westin St. Francis Hotel in San Francisco, California, January 12-15, 2026. To learn more, visit Healthcare Conference.
Martha G. Aronson, President and Chief Executive Officer, and Raul Parra, Chief Financial Officer, will present a company overview and update on Tuesday, January 13th at 4:30 pm Pacific Time / 7:30 pm Eastern Time.
Presentation materials for the conference will be posted to Merit’s investor relations website, Investor Events and Presentations - Merit Medical. A live audio webcast of the presentation will be accessible under the “Events” section of Merit’s investor relations website at Investor Events and Presentations - Merit Medical. A replay of the presentation will be available on this same website for approximately 90 days.
ABOUT MERIT MEDICAL
Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of proprietary medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves customers worldwide with a domestic and international sales force and clinical support team totaling more than 800 individuals. Merit employs approximately 7,400 people worldwide.
CONTACTS
PR/Media Inquiries
Sarah Comstock
Merit Medical Systems, Inc.
+1-801-432-2864 | sarah.comstock@merit.com
Investor Inquiries
Mike Piccinino, CFA, IRC
Westwicke - ICR
+1-443-213-0509 | mike.piccinino@icrhealthcare.com
FAQ
When will Merit Medical (MMSI) present at the J.P. Morgan Healthcare Conference in 2026?
Who will present for Merit Medical (MMSI) at the January 13, 2026 presentation?
How can investors access Merit Medical's (MMSI) J.P. Morgan presentation webcast?
Will Merit Medical (MMSI) post presentation materials from the J.P. Morgan event?
How long will Merit Medical's (MMSI) J.P. Morgan presentation replay remain available?
